Long-term cenobamate retention, efficacy, and safety: outcomes from Expanded Access Programme
CONCLUSIONS AND CLINICAL IMPLICATIONS: Long-term effectiveness, including ≥ 50% seizure reduction and a 100% retention rate, was sustained over 41 months of CNB treatment within the Expanded Access Programme. No new safety issues were identified. These results provide support for the potential long-term clinical benefits of cenobamate.PMID:38112647 | DOI:10.5603/pjnns.97121
Source: Neurologia i Neurochirurgia Polska - Category: Neurology Authors: Anetta Lasek-Bal Barbara K ściuk Tomasz Zieli ński Agnieszka Krzak-Kubica Jacek Kowalski Barbara Żorniak-Milach Katarzyna Maciejowska Maciej Maciejowski Anna Wagner-Kusz Magdalena Bosak Source Type: research
More News: Brain | Carbamazepine | Epilepsy | Eye Laser Surgery | Headache | Migraine | Neurology | Poland Health | Study